Login to Your Account

Seeing a diff in C. difficile: Space heats up as Summit lays out phase III roadmap

By Randy Osborne
Staff Writer

Wednesday, February 1, 2017

"We're doing the bold thing" by going for phase III superiority [rather than non-inferiority] vs. standard of care with an antibiotic in C. diff infection, Summit Therapeutics plc CEO Glyn Edwards told BioWorld Today.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription